Tuesday, 11 February 2014

Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision

Egeneron Pharmaceuticals and Bayer HealthCare announced that in the Phase 3 VISTA-DME trial of EYLEA® (aflibercept) injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections0 showed a sustained improvement from baseline in best corrected visual acuity at week 100, compared to laser photocoagulation (Egeneron)

No comments:

Post a Comment